Michael Schmitt

List of Publications by Year
in descending order

131 papers	3,502 citations	186265 28 h-index	161849 54 g-index
131 all docs	131 docs citations	131 times ranked	4451 citing authors

#	Article	IF	Citations
1	Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells. Cytotherapy, 2022, 24, 311-319.	0.7	7
2	<scp>CD33</scp>â€directed immunotherapy with thirdâ€generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and <scp>CD33</scp>â€edited acute myeloid leukemia and hematopoietic stem and progenitor cells. International Journal of Cancer, 2022, 150, 1141-1155.	5.1	13
3	Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV. International Journal of Molecular Sciences, 2022, 23, 1029.	4.1	1
4	Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells. International Journal of Molecular Sciences, 2022, 23, 903.	4.1	7
5	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. Biomedicines, 2022, 10, 373.	3.2	2
6	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. Vaccines, 2022, 10, 330.	4.4	9
7	Comparison of single copy geneâ€based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19â€directed CAR T cells in treated patients. International Journal of Oncology, 2022, 60, .	3.3	5
8	GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood, 2022, , .	1.4	51
9	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapyâ€”A Cohort Study. Frontiers in Immunology, 2022, 13, 877477.	4.8	17
10	Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers. Cancers, 2022, 14, 208.	3.7	5
11	First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience. Cancer Immunology, Immunotherapy, 2022, 71, 2913-2928.	4.2	8
12	Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Annals of Hematology, 2021, 100, 2087-2093.	1.8	29
13	The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. Bone Marrow Transplantation, 2021, 56, 30-37.	2.4	5
14	Comments on â€œCost of decentralized <scp>CAR</scp> T cell production in an academic nonâ€profit settingâ€. International Journal of Cancer, 2021, 148, 514-515.	5.1	4
15	Ibrutinib for improved chimeric antigen receptor Tâ€cell production for chronic lymphocytic leukemia patients. International Journal of Cancer, 2021, 148, 419-428.	5.1	42
16	Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients. Vaccines, 2021, 9, 133.	4.4	8
17	A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature, 2021, 592, 463-468.	27.8	232
18	CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 2021, 138, 318-330.	1.4	98

#	Article	IF	Citations
19	An Endoplasmic Reticulum Specific Proâ€amplifier of Reactive Oxygen Species in Cancer Cells. Angewandte Chemie - International Edition, 2021, 60, 11158-11162.	13.8	34
20	Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma. Cancers, 2021, 13, 1684.	3.7	17
21	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. Frontiers in Immunology, 2021, 12, 670088.	4.8	10
22	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) TÂcells for CD19â€‘positive malignancies. Oncology Reports, 2021, 46, .	2.6	12
23	Fatal late-onset CAR T-cellâ€“mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma. Blood Advances, 2021, 5, 3789-3793.	5.2	10
24	Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. Cells, 2021, 10, 152.	4.1	2
25	Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR. Cells, 2021, 10, 3208.	4.1	13
26	Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy. Blood, 2021, 138, 3861-3861.	1.4	1
27	First-in-Human Study of WT1 Recombinant Protein Vaccination in Elderly Patients with AML in Remission: A Single-Center Experience. Blood, 2021, 138, 1278-1278.	1.4	4
28	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). Blood, 2021, 138, 1810-1810.	1.4	0
29	A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 828.	1.6	16
30	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. Cancers, 2020, 12, 2820.	3.7	13
31	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. Blood Advances, 2020, 4, 6157-6168.	5.2	26
32	Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. Frontiers in Immunology, 2020, 11, 608167.	4.8	23
33	Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL. Cells, 2020, 9, 1225.	4.1	40
34	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1575-1580.	2.0	20
35	Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients. Molecular Therapy - Methods and Clinical Development, 2020, 17, 448-454.	4.1	28
36	Bâ€cell maturation antigenâ€specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. International Journal of Cancer, 2020, 147, 2029-2041.	5.1	10

#	Article	IF	Citations
37	Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL). Blood, 2020, 136, 11-12.	1.4	2
38	Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells. Blood, 2020, 136, 33-34.	1.4	11
39	Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. International Journal of Cancer, 2019, 144, 1135-1146.	5.1	12
40	Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. Cancer Immunology, Immunotherapy, 2019, 68, 1195-1209.	4.2	27
41	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. BMJ Open, 2019, 9, e026644.	1.9	27
42	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. International Journal of Molecular Sciences, 2019, 20, 2469.	4.1	14
43	Regulatory T cells sense effector Tâ€cell activation through synchronized JunB expression. FEBS Letters, 2019, 593, 1020-1029.	2.8	12
44	Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy, 2019, 21, 566-578.	0.7	23
45	Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. Frontiers in Immunology, 2019, 10, 547.	4.8	16
46	Idelalisib for optimized CD19â€specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. International Journal of Cancer, 2019, 145, 1312-1324.	5.1	67
47	Identification of Boronic Acid Derivatives as an Active Form of N-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with ¹⁸F. Bioconjugate Chemistry, 2019, 30, 1077-1086.	3.6	21
48	Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). Journal of Clinical Medicine, 2019, 8, 200.	2.4	80
49	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 6223.	4.1	88
50	Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy. Blood, 2019, 134, 3226-3226.	1.4	2
51	Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients. Blood, 2019, 134, 51-51.	1.4	30
52	The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis. Blood, 2019, 134, 3328-3328.	1.4	1
53	Cell therapeutic approaches to immunosuppression after clinical kidney transplantation. Pediatric Nephrology, 2018, 33, 199-213.	1.7	13
54	Chimeric antigen receptor transduced T cells: Tuning up for the next generation. International Journal of Cancer, 2018, 142, 1738-1747.	5.1	49

#	Article	IF	Citations
55	Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells. Frontiers in Immunology, 2018, 9, 2734.	4.8	23
56	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. Frontiers in Immunology, 2018, 9, 2207.	4.8	21
57	Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. Human Gene Therapy, 2018, 29, 1167-1182.	2.7	19
58	Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. EBioMedicine, 2018, 32, 125-133.	6.1	6
59	Development of Potency Assays for Quality Assessment of an Advanced Therapy Medicinal Product: Mitomycin C-Induced Peripheral Blood Mononuclear Cell (MIC) Product. Blood, 2018, 132, 5689-5689.	1.4	0
60	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. Blood, 2018, 132, 3399-3399.	1.4	1
61	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion â€" a Phase I Study (TOL-1). Blood, 2018, 132, 4539-4539.	1.4	0
62	Treg Downregulation Was Associated with Augmentation of T Cell Responses Against Immunogenic Antigens and Clinical Responses in Patients with Hematological Malignancies after Donor Lymphocyte Infusion (DLI). Blood, 2018, 132, 3423-3423.	1.4	0
63	Next-generation dendritic cell-based vaccines for leukemia patients. Immunotherapy, 2017, 9, 173-181.	2.0	9
64	Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. Haematologica, 2017, 102, e499-e501.	3.5	26
65	Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses. Theranostics, 2017, 7, 1705-1718.	10.0	13
66	Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients. Frontiers in Immunology, 2017, 8, 1956.	4.8	79
67	Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance. Oncotarget, 2017, 8, 2485-2500.	1.8	7
68	Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28â^' T-cells. Oncotarget, 2017, 8, 98200-98214.	1.8	15
69	Standardization of cryopreserved peripheral blood mononuclear cells through a resting process for clinical immunomonitoringâ€"Development of an algorithm. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 246-258.	1.5	46
70	Immune responses to <scp>WT1</scp> in patients with <scp>AML</scp> or <scp>MDS</scp> after chemotherapy and allogeneic stem cell transplantation. International Journal of Cancer, 2016, 138, 1792-1801.	5.1	42
71	Versican vs versikine: tolerance vs attack. Blood, 2016, 128, 612-613.	1.4	14
72	Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation. Human Gene Therapy, 2016, 27, 758-771.	2.7	34

#	Article	IF	Citations
73	Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. Expert Opinion on Biological Therapy, 2016, 16, 1113-1123.	3.1	9
74	Indoleamine 2,3-dioxygenase mediates inhibition of virus-specific CD8+ T cell proliferation by human mesenchymal stromal cells. Cytotherapy, 2016, 18, 621-629.	0.7	24
75	Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. Journal of Translational Medicine, 2016, 14, 99.	4.4	8
76	Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells. Blood, 2016, 128, 3509-3509.	1.4	0
77	Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor. Blood, 2016, 128, 2519-2519.	1.4	0
78	Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica, 2015, 100, e285-e288.	3.5	43
79	Standardization of Good Manufacturing Practiceâ€“compliant production of bone marrowâ€“derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy, 2015, 17, 128-139.	0.7	118
80	T cellâ€based targeted immunotherapies for patients with multiple myeloma. International Journal of Cancer, 2015, 136, 1751-1768.	5.1	10
81	Modulation of lymphocyte subpopulations by extracorporeal photopheresis in patients with acute graft-versus-host disease or graft rejection. Leukemia and Lymphoma, 2015, 56, 671-675.	1.3	19
82	Suppression of cytomegalovirus-specific CD8+T cells by everolimus. Leukemia and Lymphoma, 2014, 55, 1144-1150.	1.3	4
83	Cellular immunotherapy for patients with reactivation of JC and BK polyomaviruses after transplantation. Cytotherapy, 2014, 16, 1325-1335.	0.7	31
84	Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. Molecular and Clinical Oncology, 2014, 2, 773-782.	1.0	8
85	Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood, 2013, 122, 1087-1088.	1.4	61
86	Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. Blood, 2012, 120, 1282-1289.	1.4	129
87	Safety and efficacy of everolimus after kidney and hematopoietic stem cell transplantation. Annals of Transplantation, 2012, 17, 52-58.	0.9	9
88	Effect of epitopes derived from the mutated region of cytoplasmatic nucleophosmine 1 (NPM1) on CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2012, 30, 6567-6567.	1.6	0
89	Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs). Blood, 2012, 120, 3592-3592.	1.4	0
90	Adoptive transfer and selective reconstitution of streptamerâ€selected cytomegalovirusâ€specific CD8+ Tâ€ƒcells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion, 2011, 51, 591-599.	1.6	198

#	Article	IF	Citations
91	The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses. Blood, 2011, 118, 2569-2569.	1.4	0
92	High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica, 2010, 95, 1191-1197.	3.5	124
93	Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Experimental Hematology, 2010, 38, 1066-1073.	0.4	22
94	Targeted cellular immunotherapy for leukemia patients. Transfusion and Apheresis Science, 2010, 43, 207-210.	1.0	3
95	Polyomavirus BK-specific CD8+ T cell responses in patients after allogeneic stem cell transplant. Leukemia and Lymphoma, 2010, 51, 1055-1062.	1.3	17
96	Cytomegalovirus vaccination of leukemia and lymphoma patients after allogeneic stem cell transplantation â€" Validation of a peptide vaccine. Journal of Immunological Methods, 2009, 343, 140-147.	1.4	8
97	Immunological and histochemical analyses of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Acta Neuropsychiatrica, 2009, 21, 51-57.	2.1	4
98	Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Experimental Hematology, 2008, 36, 1297-1308.	0.4	77
99	Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells: Fig. 1.. Clinical Cancer Research, 2008, 14, 7161-7166.	7.0	89
100	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood, 2008, 111, 1357-1365.	1.4	202
101	Adoptive Transfer and Consequential Selective Reconstitution of Streptamer-Selected Cytomegalovirus-Specific CD8+ T Cells Leads to Enduring Virus Clearance in Patients after Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 1181-1181.	1.4	4
102	Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 3159-3159.	1.4	2
103	Levofloxacine Prophylaxis Decreases the Incidence of BK Polyoma Virus-Induced Hemorrhagic Cystitis in Patients after Allogeneic Hematopoietic Stem Cell Trans-Plantation. Blood, 2008, 112, 4343-4343.	1.4	4
104	Peptide Vaccine Preparation and Validation with a Bio-Assay. Blood, 2008, 112, 5444-5444.	1.4	0
105	The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies.. Blood, 2008, 112, 1524-1524.	1.4	0
106	Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia. Biomarker Insights, 2007, 2, 117727190700200.	2.5	6
107	Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunology, Immunotherapy, 2007, 56, 849-861.	4.2	24
108	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. Blood, 2007, 110, 1806-1806.	1.4	9

#	Article	IF	Citations
109	Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-Î¹B Pathway.. Blood, 2007, 110, 2368-2368.	1.4	1
110	Streptamer Technology for the Assessment of CMVpp65 Specific CD8+ T Cell Frequencies and for the Adoptive T Cell Transfer to Post-Transplant Patients.. Blood, 2007, 110, 1964-1964.	1.4	0
111	The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.. Blood, 2007, 110, 2051-2051.	1.4	0
112	Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.. Blood, 2007, 110, 2052-2052.	1.4	0
113	Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.. Blood, 2006, 108, 5471-5471.	1.4	0
114	High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.. Blood, 2006, 108, 2108-2108.	1.4	0
115	RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2773-2773.	1.4	0
116	Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.. Blood, 2006, 108, 2201-2201.	1.4	0
117	RHAMM/CD168-R3 Peptide Vaccination of Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) Elicits Immunological and Clinical Responses.. Blood, 2006, 108, 409-409.	1.4	0
118	Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.. Blood, 2006, 108, 414-414.	1.4	0
119	Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica, 2006, 91, 1653-61.	3.5	70
120	Identification and characterization of epitopes of the receptor for hyaluronic acidâ€“mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2â€“positive patients with acute myeloid leukemia. Blood, 2005, 106, 938-945.	1.4	105
121	RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).. Blood, 2005, 106, 2781-2781.	1.4	7
122	The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 53-53.	1.4	1
123	Chronic Myeloid Leukemia (CML) Cells Express Tumor Associated Antigens Eliciting Specific CD8+ T Cell Responses Despite of Deficient Expression of Costimulatory Molecules.. Blood, 2005, 106, 2886-2886.	1.4	0
124	mRNA expression of leukemiaâ€associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. International Journal of Cancer, 2004, 108, 704-711.	5.1	118
125	Dendritic Cells (DC) Generated from AML Blasts Express Leukemia Associated Antigens Eliciting Specific Cytotoxic T Cell Responses in the Autologous Host after DC Vaccination.. Blood, 2004, 104, 1812-1812.	1.4	4
126	Characterization of T Cell Epitopes of the Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) in Acute Myeloid Leukemia.. Blood, 2004, 104, 2540-2540.	1.4	2

#	Article	IF	Citations
127	Characterization of several leukemiaâ€associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. International Journal of Cancer, 2003, 106, 224-231.	5.1	84
128	Receptor for hyaluronan acidâ€“mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Experimental Hematology, 2002, 30, 1029-1035.	0.4	126
129	Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone marrow transplantation: Reminiscence of gut-associated acute graft-versus-host reaction. International Journal of Oncology, 2002, 21, 795-801.	3.3	1
130	Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemotherapy and Pharmacology, 2000, 46, S77-S82.	2.3	43
131	Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 0, , .	2.4	2